Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - Aquestive Therapeutics (NASDAQ: AQST) reported first quarter EPS of $-0.190, $0.06 worse than the analyst estimate of $-0.130. Revenue for the quarter came in at $11.87M versus the consensus estimate of $13.08M.
Aquestive Therapeutics’s stock price closed at $2.79. It is down -33.090% in the last 3 months and down -44.530% in the last 12 months.
Aquestive Therapeutics saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Aquestive Therapeutics’s stock price’s past reactions to earnings here.
According to InvestingPro, Aquestive Therapeutics’s Financial Health score is "good performance".
Check out Aquestive Therapeutics’s recent earnings performance, and Aquestive Therapeutics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar